Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials

Fig. 2

Changes from baseline in PROs up to month 12. LS mean change from baseline in a FACIT-F total score, b MOS-SS Sleep Problems Index I scorea, c MOS-SS Sleep Problems Index II scoreb, d SF-36 PCS score, and e SF-36 MCS score to month 12 across treatment groupsc pooled from Phase 3 ORAL Scan, ORAL Standard, and ORAL Sync study datasets (full analysis set). aBased on six items of the MOS-SS: How often over the past 4 weeks did you … have trouble falling asleep; awaken during sleep; awaken short of breath/with headache; get enough sleep to feel rested upon waking; get amount of sleep needed; have trouble staying awake? bBased on the six items stated in footnote a and three additional items of the MOS-SS: How often over the past 4 weeks did you … feel that your sleep was not quiet; feel drowsy during day; how long did it usually take to fall asleep? cAll treatments were administered in combination with background conventional synthetic disease-modifying antirheumatic drugs. * p < 0.05, ** p < 0.01, and *** p < 0.001 for tofacitinib and adalimumab vs placebo; p < 0.05 and †† p < 0.01 for tofacitinib vs adalimumab. The horizontal dashed lines represent the MCIDs. The arrows on the y-axes indicate the direction of improvement. ADA, adalimumab; BID, twice daily; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; LS, least squares; MCID, minimum clinically important difference; MCS, Mental Component Summary; MOS-SS, Medical Outcomes Study Sleep scale; PCS, Physical Component Summary; PRO, patient-reported outcome; Q2W, once every 2 weeks; SE, standard error; SF-36, Short Form-36 Health Survey

Back to article page